FDA premarket records identify Synovis Life Technologies, Inc. (Baxter International Inc.) as the applicant on K260431, a Traditional premarket notification for the Dura-Guard Dural Repair Patch. The submission was received on 27 January 2026 and decided on 5 November 2026 with a Substantially Equivalent decision. The applicant address in that filing is 2575 University Ave. W., St. Paul, Minnesota 55114, and the product carries product code GXQ with device class 2. [1][2]

The applicant and its registered establishment

The establishment registration database lists SYNOVIS LIFE TECHNOLOGIES, INC. (A Subsidiary of Baxter International Inc.) at 2575 University Ave W, Saint Paul, MN 55114, with registration number 2183620 and business trade name Synovis Surgical Innovations. The same record names BAXTER HEALTHCARE CORPORATION as owner/operator and lists the establishment operation as Manufacturer. The registration page was last updated 2 March 2026. [5][2]

Instructions for use documents carry the Synovis Life Technologies, Inc. name with the parenthetical A Subsidiary of Baxter International Inc., alongside the St. Paul address and Baxter contact numbers. Baxter and Dura-Guard are identified in those documents as trademarks of Baxter International Inc. or its subsidiaries. The applicant identity and the parent brand are therefore documented separately rather than treated as interchangeable. [6][8]

Dura-Guard Dural Repair Patch

The device listing record gives the proprietary name Dura-Guard-Dural Repair Patch, classification name Dura Substitute, product code GXQ, device class 2, regulation number 882.5910 and medical specialty Neurology. The premarket submission number shown on that listing is K982282. The listing identifies the registered establishment as a manufacturer of the device. [2]

Baxter product material describes DURA-GUARD Dural Repair Patch as for use as a dura substitute for the closure of dura during neurosurgery, with applicable procedures listed as tumor resection, trauma and congenital disorders. The same page places the patch within the Tissue Guard Family of Surgical Patches and states that the family covers vascular, neurological, thoracic and cardiothoracic surgery. [4]

A Baxter catalog entry identifies a specific model, DURA-GUARD Dural Repair Patch 2x9cm, under the catalog reference DG0209SN. The catalog page carries a disclaimer that images and labels are illustrative and may not be an exact representation of the product. [9]

Submission and labeling scope

K260431 is recorded as a Traditional clearance with no third-party review, advisory committee NE (Neurology), and a review advisory committee of Neurology. The decision code is SESE with the description Substantially Equivalent, and the statement field indicates a Summary. The expedited review flag is blank in the record. [1]

The supplied collection contains one linked 510(k) record, K260431, and its decision count is one Substantially Equivalent decision; the record sample is the same single entry. These figures describe the supplied filings as of the snapshot date and are not measures of total company sales, total portfolio or safety performance. [1]

Labeling documents state that the patch does not interfere with medical or electrical equipment and that European Union patients receive a Patient Implant Card identifying the implanted device model number next to the REF symbol. The same booklet refers readers to Table 1 for the amount of tissue a patient may be exposed to by model number and patch dimensions. [7]

Corporate and regional documentation

European labeling identifies a Basic UDI-DI for the device and directs EU patients to the Summary of Safety and Clinical Performance via EUDAMED after launch. The document includes a warranty disclaimer stating that reasonable care has been used in manufacture and that no product is 100 percent effective under all circumstances because of biological differences in individuals. [6]

The same labeling names Baxter Deutschland GmbH in Unterschleissheim, Germany, Baxter Healthcare Ltd. in Thetford, United Kingdom, and Baxter Healthcare SA in Glattpark, Switzerland, with United Kingdom Responsible Person and Swiss EC REP designations. These are labeling contacts, not statements about where the applicant is headquartered. [7]